Medication Affordability and Patent Integrity Act

U.S. Congress · S2658 · Floor

What the bill says

S2658 · U.S. Congress · Floor

Introduced 2025-08-01. Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.

View on Congress.gov →

Sponsors

Text versions

  • Introduced in Senate — 2025-08-01 — XML
  • Reported to Senate — 2026-07-28 — XML

What analysts say

No nonpartisan analysis on file for this measure yet.

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2026-07-28Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
2026-07-28Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.
2026-06-17Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2026-03-19Committee on Health, Education, Labor, and Pensions. Hearings held.
2025-08-01Introduced in Senate
2025-08-01Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Lobbying on this bill

Showing 25 of 63 bill mentions.

Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.

Registrant (lobbying firm)ClientPeriodReported quarterly amountExtraction
DAVE KOLBE CONSULTING PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION Q2 2026 $30,000 Explicit
E3 STRATEGIC CONSULTING GROUP PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION Q2 2026 $60,000 Explicit
BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. BLUE CROSS AND BLUE SHIELD OF KANSAS INC Q2 2026 $10,000 Explicit
INTELLECTUAL PROPERTY OWNERS ASSOCIATION INTELLECTUAL PROPERTY OWNERS ASSOCIATION Q2 2026 $50,000 Explicit
CENTER FOR INDIVIDUAL FREEDOM CENTER FOR INDIVIDUAL FREEDOM Q2 2026 $20,000 Explicit
GSK (FKA GLAXOSMITHKLINE INC.) GSK (FKA GLAXOSMITHKLINE INC.) Q2 2026 $890,000 Explicit
GSK (FKA GLAXOSMITHKLINE INC.) GSK (FKA GLAXOSMITHKLINE INC.) Q2 2026 $890,000 Explicit
S-3 GROUP FRESENIUS KABI Q2 2026 $30,000 Explicit
S-3 GROUP FRESENIUS KABI Q2 2026 $30,000 Explicit
BCBSM, INC. BCBSM INC Q2 2026 $28,000 Explicit
CROSSROADS STRATEGIES, LLC PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Q2 2026 $50,000 Explicit
TIBER CREEK GROUP PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION Q2 2026 $50,000 Explicit
TIBER CREEK GROUP PHRMA Q2 2026 $110,000 Explicit
TIBER CREEK GROUP TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) Q2 2026 $80,000 Explicit
RADIUS ADVOCACY, LLC COUNCIL FOR INNOVATION PROMOTION (C4IP) Q2 2026 $50,000 Explicit
RADIUS ADVOCACY, LLC PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Q2 2026 $30,000 Explicit
TRAVERE THERAPEUTICS TRAVERE THERAPEUTICS Q2 2026 $140,000 Explicit
GUIDEWELL MUTUAL HOLDING CORPORATION GUIDEWELL MUTUAL HOLDING CORPORATION Q2 2026 $20,000 Explicit
FIERCE GOVERNMENT RELATIONS ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) Q2 2026 $60,000 Explicit
BLUE CROSS AND BLUE SHIELD ASSOCIATION BLUE CROSS AND BLUE SHIELD ASSOCIATION Q2 2026 $990,000 Explicit
PFIZER INC. PFIZER INC. Q2 2026 $1,880,000 Explicit
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS Q2 2026 $260,000 Explicit
EISAI INC. EISAI INC. Q2 2026 $790,000 Explicit
INCYTE CORPORATION INCYTE CORPORATION Q2 2026 $750,000 Explicit
SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL) SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL) Q2 2026 $45,000 Explicit

Source: Senate LDA filings.